The ability of the combination therapy to inhibit tumor growth was significantly abrogated by uridine supplementation (Figure 5A and Supplemental Figure 5, B and F), indicating that the effects of BRQ in this therapeutic paradigm acted through inhibition of DHODH. Here, DHODH is linked to neoplasm.